SIRT3 and Parkinson disease: In addition, Park and colleagues showed that the activation of SIRT-3 by the AMPK/CREB-PGC-1α signalling results in reduced αsyn oligomers in PD, suggesting that the use of SIRT-3 activators may represent a potential therapy to restore mitochondrial deficits and decrease αsyn-induced pathophysiology [145].